TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
DYN

Dyne Therapeutics Inc

Healthcare · Biotechnology

16.50$ +1.7% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

All figures as a percentage of total assets in the same period.

Tick rows to compare them in a chart (up to 4)

Balance Sheet DYN
Line item 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
12.6% 19.7% 18.6% 22.4% 16.3% 23.0% 31.8% 23.8% 16.9% 22.9% 12.9% 98.7% 89.8% 98.8% 89.8% 86.7% 78.4% 95.4% 94.9%
2.5% 4.9% 4.3% 2.9% 9.6% 7.7% 15.9% 16.6% 4.4% 13.6% 3.1% 98.3% 89.0% 85.1% 47.2% 56.2% 73.7% 63.0% 75.3%
3.3% 5.5% 5.0% 4.0% 11.3% 8.0% 16.4% 17.3% 5.2% 14.6% 3.4% 98.3% 89.0% 97.7% 88.5% 83.6% 74.6% 92.9% 93.6%
3.2% 2.4% 1.9% 2.3% 0.1% 2.4% 7.9% 2.4% 3.5% 3.0% 4.4% – – – – – – – –
1.5% 1.3% 1.3% 1.2% 1.4% 2.2% 3.4% 1.9% 5.2% 3.4% 3.8% – – – – – – – –
– – – – – – – – – – – 1.3% 9.0% 0.6% 9.6% 12.5% – – –
3.3% 3.0% – – – – – – 6.9% 6.1% 6.6% – – – – – – – –
3.8% 3.1% 3.5% 1.4% – 6.0% 2.0% 0.2% 0.9% 0.3% 0.2% – – – – – – – –
65.7% 68.4% 72.8% 72.6% 73.1% 44.8% 58.2% 73.1% 74.7% 84.4% 83.9% 159.0% 14.6% 3.1% 13.5% 17.6% 44.7% 8.9% 18.1%
7.6% 12.0% 16.9% 15.6% 3.9% 7.7% 13.6% 6.1% 7.0% 7.0% 8.9% 8.6% 14.3% 3.1% 6.7% 9.2% 31.0% 6.1% 4.3%
0.4% 0.5% 7.4% 1.5% 0.1% 0.6% 0.2% 0.3% 0.7% 1.5% 0.9% – – – 0.9% 1.5% 2.9% 0.7% 0.4%
2.2% 2.1% 1.7% 1.3% 0.4% 2.5% 6.2% 1.9% 2.5% 2.5% 3.1% 6.3% 7.6% 1.0% 0.9% 1.7% 13.9% 0.9% 0.7%
– – – – – – – – – – – – – – – – – – 12.5%
34.1% 31.8% 26.5% 27.4% 26.9% 55.2% 41.8% 26.9% 25.3% 15.6% 16.1% -59.0% 85.4% 96.9% 86.5% 82.4% 55.3% 91.1% 81.9%
– – – -31.9% -117.3% -2.4% -8.8% -6.6% -5.9% -14.8% -15.7% -59.1% -120.1% -22.4% -53.7% -129.5% -383.1% -137.4% -117.6%
7.9% 6.1% 9.2% 1.2% 3.0% 2.2% 1.9% 1.1% 1.1% 1.0% 1.4% 124.9% 276.4% 13.4% 12.0% 17.0% 36.2% 13.6% 10.8%

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?